Renal and Neurologic Benefit of Levosimendan vs Dobutamine in Patients With Low Cardiac Output Syndrome After Cardiac Surgery: Clinical Trial FIM-BGC-2014-01

• Main Authors: Jose L. Guerrero-Orriach (Author), Alfredo Malo-Manso (Author), Marta Ramirez-Aliaga (Author), Ana Isabel Florez Vela (Author), Manuel Galán-Ortega (Author), Isabel Moreno-Cortes (Author), Inmaculada Gonzalez-Almendros (Author), Alicia Ramirez-Fernandez (Author), Daniel Ariza-Villanueva (Author), Juan Jose Escalona-Belmonte (Author), Guillermo Quesada-Muñoz (Author), Enrique Sepúlveda-Haro (Author), Salvador Romero-Molina (Author), Inmaculada Bellido-Estevez (Author), Aurelio Gomez-Luque (Author), Manuel Rubio-Navarro (Author), Juan Alcaide-Torres (Author), Concepcion Santiago-Fernandez (Author), Lourdes Garrido-Sanchez (Author), Jose Cruz-Mañas (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundLow-cardiac output syndrome (LCOS) after cardiac surgery secondary to systemic hypoperfusion is associated with a higher incidence of renal and neurological damage. A range of effective therapies are available for LCOS. The beneficial systemic effects of levosimendan persist even after car...